ClinicalTrials.gg
CompletedNCT01561963Updated Jun 9, 2021Results posted

A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast

A Phase 1 interventional study of Apremilast and Rifampin Oral Capsules in Healthy Subjects, sponsored by Amgen. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Amgen · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate how the pharmacokinetics of apremilast may be affected by a single intravenous dose of rifampin and multiple oral doses of rifampin.

02

Conditions studied

  • Healthy Subjects

Keywords

  • Apremilast
  • drug interaction
  • pharmacokinetics
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects of any ethnic origin between ages of 18 and 55 with a between 18 and 33

Exclusion criteria

Exclusion Criteria:

  • Recent history (i.e., within 3 years) of any neurological, gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, endocrine, hematological, dermatological, psychological, allergic or other major disorders.
  • Use of any prescribed or non-prescribed systemic or topical medication (including vitamins and herbal medicines, e.g. St. John's Wort) within 30 days of the first dose, unless an exception is granted by the sponsor.
  • Presence of any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism, and excretion, or plans to have elective or medical procedures during the conduct of the trial.
  • Exposure to an drug (new chemical entity) within 30 days prior to the first dose administration
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Apremilast and Rifampin

    Participants received the following 3 treatment regimens: * A single oral dose of 30 mg apremilast on Day 1 (Period 1); * A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 (Period 2); * Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 (Period 3).

    Drug: Apremilast · Drug: Rifampin Oral Capsules · Drug: Rifampin IV Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUCt) of Apremilast

    Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.

    Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20

  2. Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC∞) of Apremilast

    Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.

    Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20

  3. Maximum Observed Plasma Concentration (Cmax) of Apremilast

    Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.

    Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20

  4. Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast

    Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.

    Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20

  5. Estimate of the Terminal Elimination Half-life (T1/2) of Apremilast in Plasma

    Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.

    Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20

  6. Apparent Total Plasma Clearance (CL/F) of Apremilast

    Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.

    Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20

  7. Apparent Volume of Distribution (Vz/F) of Apremilast

    Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.

    Time frame: Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20

07

Results

Posted Jun 9, 2021

Participant flow

This study was conducted at one clinical site in Overland Park, Kansas, USA.

Participant flow — Overall Study
MilestoneApremilast and Rifampin
Started21
Received period 1 treatment21
Received period 2 treatment20
Received period 3 treatment20
Completed20
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUCt) of Apremilast

Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.

Time frame:
Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUCt) of Apremilast
ng*h/mLApremilast AloneApremilast + IV RifampinApremilast + Multiple Dose Oral Rifampin
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUCt) of Apremilast3070 ± 31.32940 ± 31.3850 ± 33.7
Statistical analysis
  • Apremilast Alone vs Apremilast + IV Rifampin · Ratio of geometric least squares means: 96.35 · 90% CI 88.56 to 104.82Apremilast + IV Rifampin / Apremilast Alone
  • Apremilast Alone vs Apremilast + Multiple Dose Oral Rifampin · Ratio of geometric least squares means: 27.88 · 90% CI 25.63 to 30.34Apremilast + Multiple Dose Oral Rifampin / Apremilast Alone
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC∞) of Apremilast

Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.

Time frame:
Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC∞) of Apremilast
ng*h/mLApremilast AloneApremilast + IV RifampinApremilast + Multiple Dose Oral Rifampin
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC∞) of Apremilast3120 ± 31.52980 ± 31.2869 ± 32.9
Statistical analysis
  • Apremilast Alone vs Apremilast + IV Rifampin · Ratio of geometric least squares means: 95.71 · 90% CI 87.99 to 104.12Apremilast + IV Rifampin / Apremilast Alone
  • Apremilast Alone vs Apremilast + Multiple Dose Oral Rifampin · Ratio of geometric least squares means: 27.96 · 90% CI 25.70 to 30.41Apremilast + Multiple Dose Oral Rifampin / Apremilast Alone
PrimaryMaximum Observed Plasma Concentration (Cmax) of Apremilast

Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.

Time frame:
Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Apremilast
ng/mLApremilast AloneApremilast + IV RifampinApremilast + Multiple Dose Oral Rifampin
Maximum Observed Plasma Concentration (Cmax) of Apremilast290 ± 24.5331 ± 25.1166 ± 23.2
Statistical analysis
  • Apremilast Alone vs Apremilast + IV Rifampin · Ratio of geometric least squares means: 113.07 · 90% CI 103.18 to 123.91Apremilast + IV Rifampin / Apremilast Alone
  • Apremilast Alone vs Apremilast + Multiple Dose Oral Rifampin · Ratio of geometric least squares means: 56.80 · 90% CI 51.84 to 62.25Apremilast + Multiple Dose Oral Rifampin / Apremilast Alone
PrimaryTime to Maximum Observed Plasma Concentration (Tmax) of Apremilast

Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.

Time frame:
Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast
hoursApremilast AloneApremilast + IV RifampinApremilast + Multiple Dose Oral Rifampin
Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast2.00 (0.50 to 5.00)1.50 (0.50 to 5.00)1.00 (0.50 to 5.00)
Statistical analysis
  • Apremilast Alone vs Apremilast + IV Rifampin · Wilcoxon signed rank test · p = 0.2656 · Median difference: -0.25 · 90% CI -0.75 to 0.00Apremilast + IV Rifampin - Apremilast Alone
  • Apremilast Alone vs Apremilast + Multiple Dose Oral Rifampin · Wilcoxon signed rank test · p = 0.1141 · Median difference: -0.50 · 90% CI -1.00 to 0.00Apremilast + Multiple Dose Oral Rifampin - Apremilast Alone
PrimaryEstimate of the Terminal Elimination Half-life (T1/2) of Apremilast in Plasma

Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.

Time frame:
Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20
Reported as:
Geometric mean · hours
Estimate of the Terminal Elimination Half-life (T1/2) of Apremilast in Plasma
hoursApremilast AloneApremilast + IV RifampinApremilast + Multiple Dose Oral Rifampin
Estimate of the Terminal Elimination Half-life (T1/2) of Apremilast in Plasma8.12 ± 14.17.35 ± 18.56.13 ± 24.8
PrimaryApparent Total Plasma Clearance (CL/F) of Apremilast

Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.

Time frame:
Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20
Reported as:
Geometric mean · L/h
Apparent Total Plasma Clearance (CL/F) of Apremilast
L/hApremilast AloneApremilast + IV RifampinApremilast + Multiple Dose Oral Rifampin
Apparent Total Plasma Clearance (CL/F) of Apremilast9.60 ± 31.510.1 ± 31.234.5 ± 32.9
PrimaryApparent Volume of Distribution (Vz/F) of Apremilast

Plasma concentrations of apremilast were determined by means of a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometric (LC-MS/MS) assay.

Time frame:
Pre-dose and at 0.5, 1, 1.5, 2, 3, 5, 8, 12, 16, 24, 36, and 48 hours following apremilast dosing on Days 1, 5, and 20
Reported as:
Geometric mean · liters
Apparent Volume of Distribution (Vz/F) of Apremilast
litersApremilast AloneApremilast + IV RifampinApremilast + Multiple Dose Oral Rifampin
Apparent Volume of Distribution (Vz/F) of Apremilast112 ± 35.8107 ± 43.4305 ± 51.6

Adverse events

Collected over Period 1 (Apremilast Alone): Day 1 to day 4; Period 2 (Apremilast + IV Rifampin): Day 5 to day 6; Period 3 (Apremilast + Multiple Dose Oral Rifampin): Day 7 up to day 32; Overall Study (All Treatment Regimens): Up to 32 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apremilast Alone—0/21 (0%)2/21 (9.5%)
Apremilast + IV Rifampin—0/20 (0%)4/20 (20%)
Apremilast + Multiple Dose Oral Rifampin—0/20 (0%)9/20 (45%)
Overall Study - All Treatment Regimens—0/21 (0%)12/21 (57.1%)
Most frequent other events
Showing 10 of 26
Most frequent other events
EventApremilast AloneApremilast + IV RifampinApremilast + Multiple Dose Oral RifampinOverall Study - All Treatment Regimens
HEADACHENervous system disorders2/211/201/204/21
RHINITISInfections and infestations0/210/202/202/21
CONJUNCTIVAL HYPERAEMIAEye disorders0/211/200/201/21
ABDOMINAL PAIN LOWERGastrointestinal disorders0/210/201/201/21
ABDOMINAL PAIN UPPERGastrointestinal disorders0/211/200/201/21
DIARRHOEAGastrointestinal disorders0/211/201/201/21
DYSPHAGIAGastrointestinal disorders0/210/201/201/21
ASTHENIAGeneral disorders0/210/201/201/21
CHILLSGeneral disorders0/210/201/201/21
FEELING HOTGeneral disorders0/210/201/201/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)Apremilast and Rifampin
Mean34 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Apremilast and Rifampin
Female1
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Apremilast and Rifampin
Hispanic or Latino1
Not Hispanic or Latino20
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Apremilast and Rifampin
White12
Black or African American9
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m²)Apremilast and Rifampin
Mean29.14 ± 2.974
08

Study locations

1 site
  • Quintiles
    Overland Park, Kansas 66211, United States
09

References and documents

Publications

  • Liu Y, Zhou S, Wan Y, Wu A, Palmisano M. The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. Br J Clin Pharmacol. 2014 Nov;78(5):1050-7. doi: 10.1111/bcp.12448. PubMed 24962564 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2012 to primary completion in Apr 2012, 2 months.

Results were first posted in Jun 2021, 9 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2012
First posted
Mar 23, 2012
StartActual
Feb 1, 2012
Primary completionActual
Apr 1, 2012
CompletionActual
Apr 1, 2012
Results first posted
Jun 9, 2021
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01561963
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 23, 2012
Start date
Feb 1, 2012
Primary completion
Apr 1, 2012
Completion
Apr 1, 2012
Results posted
Jun 9, 2021
Last update
Jun 9, 2021

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion